Scancell Holdings plc Logo

Scancell Holdings plc

SCLP.L

(1.0)
Stock Price

16,25 GBp

-48.01% ROA

190.73% ROE

-9.59x PER

Market Cap.

123.172.000,00 GBp

-566.79% DER

0% Yield

-214.72% NPM

Scancell Holdings plc Stock Analysis

Scancell Holdings plc Fundamental Analysis

Fundamental analysis in stock investing is like studying the foundation of a house before buying it. It involves looking at a company's financial health, like its earnings, assets, and debts, to determine if it's a good investment based on its fundamental strength and potential for growth.

Scancell Holdings plc Fundamental Stock Analysis
# Analysis Rating
1 PBV

With a remarkably low PBV ratio (-16.69x), the stock offers substantial upside potential at a bargain price.

2 DER

The stock has a low debt to equity ratio (-313%), which means it has a small amount of debt compared to the ownership it holds

3 ROE

Negative ROE (-180.14%) indicates poor financial performance, raising concerns about profitability and efficiency in utilizing shareholders' equity.

4 ROA

The stock's ROA (-44.45%) indicates that it's not effectively utilizing its assets to generate profits, making it a less favorable option to invest and earn consistent returns.

5 Revenue Growth

Regrettably, this company's revenue has shown no signs of growth over the past three years, suggesting limited potential for returns and making it a less appealing choice.

6 Net Profit Growth

Despite the passage of five years, this company's net profit has not shown any improvement, highlighting a lack of growth and making it a less appealing investment prospect.

7 Assets Growth

Company's revenue has remained stagnant over the past three years, indicating a lack of growth and making it a less favorable option.

8 Graham Number

The Graham number analysis indicates that this company's stock price is likely overpriced, raising concerns about its investment potential.

9 Dividend Growth

Investors should note the company's stagnant dividend growth over the past three years, indicating limited profitability and potentially diminishing returns.

10 Dividend

The company's lack of dividends in the past three years may concern investors seeking regular income.

11 Buffet Intrinsic Value

The company's stock presents a potential concern as it appears overvalued (0) by Warren Buffett's formula, indicating that its market price exceeds its estimated intrinsic value.

Scancell Holdings plc Technical Analysis

Technical analysis in stock investing is like reading the patterns on a weather map to predict future weather conditions. It involves studying past stock price movements and trading volumes to make predictions about where a stock's price might go next, without necessarily looking at the company's financial health.

Scancell Holdings plc Technical Stock Analysis
# Analysis Recommendation
1 Awesome Oscillator Hold
2 MACD Buy
3 RSI Hold
4 Stoch RSI Hold

Scancell Holdings plc Price Chart

Financial Statements

Financial statements are like report cards for companies. They show how much money a company makes (income statement), what it owns and owes (balance sheet), and where it spends its money (cash flow statement), helping stock investors understand if a company is healthy and worth investing in.

Income Statements

An income statement for a company is like a scoreboard for its profits and losses. It shows how much money the company made (revenue) and how much it spent to make that money (expenses), helping stock investors see if a company is making a profit or not.

Revenue in stock investing is the total amount of money a company earns from its sales, and it's a key factor that investors consider to assess a company's financial performance and growth potential.

Scancell Holdings plc Revenue
Year Revenue Growth
2008 0
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2020 0 0%
2021 0 0%
2022 5.271.000 100%
2023 0 0%

Research and Development Expenses are the costs a company incurs to create and improve its products or services, which can be important for investors to evaluate a company's innovation and potential for future growth.

Scancell Holdings plc Research and Development Expenses
Year Research and Development Expenses Growth
2008 676.000
2009 1.091.000 38.04%
2010 849.000 -28.5%
2011 1.221.339 30.49%
2012 1.452.317 15.9%
2013 1.677.115 13.4%
2014 1.998.366 16.08%
2015 2.009.046 0.53%
2016 2.766.098 27.37%
2017 2.855.264 3.12%
2018 4.151.950 31.23%
2019 4.667.000 11.04%
2020 4.667.000 0%
2020 6.406.000 27.15%
2021 9.477.000 32.4%
2022 11.645.000 18.62%
2023 22.772.000 48.86%

General and Administrative Expenses are the costs a company incurs to run its day-to-day operations, such as office rent, salaries, and utilities, which investors consider to understand a company's overall efficiency and management effectiveness.

Scancell Holdings plc General and Administrative Expenses
Year General and Administrative Expenses Growth
2008 0
2009 0 0%
2010 12.000 100%
2011 740.132 98.38%
2012 731.672 -1.16%
2013 820.105 10.78%
2014 961.629 14.72%
2015 1.034.117 7.01%
2016 1.782.738 41.99%
2017 2.086.536 14.56%
2018 2.577.062 19.03%
2019 2.115.000 -21.85%
2020 2.115.000 0%
2020 3.346.000 36.79%
2021 4.787.000 30.1%
2022 5.021.000 4.66%
2023 0 0%

EBITDA stands for Earnings Before Interest, Taxes, Depreciation, and Amortization. It is a measure that helps stock investors analyze a company's profitability by looking at its earnings without considering certain expenses. This helps to get a clearer picture of the company's financial performance and its ability to generate cash flow.

Scancell Holdings plc EBITDA
Year EBITDA Growth
2008 -863.000
2009 -1.782.000 51.57%
2010 -1.691.000 -5.38%
2011 -1.961.471 13.79%
2012 -2.183.989 10.19%
2013 -2.497.220 12.54%
2014 -2.959.995 15.63%
2015 -3.043.163 2.73%
2016 -4.548.836 33.1%
2017 -4.941.800 7.95%
2018 -6.707.952 26.33%
2019 -6.739.000 0.46%
2020 -6.725.000 -0.21%
2020 -14.905.000 54.88%
2021 -7.312.000 -103.84%
2022 -10.734.000 31.88%
2023 -30.744.000 65.09%

Gross profit is the money a company makes from selling its products or services after subtracting the cost of producing or providing them, and it is an important measure for investors to understand a company's profitability.

Scancell Holdings plc Gross Profit
Year Gross Profit Growth
2008 -676.000
2009 -1.091.000 38.04%
2010 -849.000 -28.5%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 -21.893 100%
2016 -32.581 32.8%
2017 -27.612 -18%
2018 -21.060 -31.11%
2019 -43.000 51.02%
2020 0 0%
2020 -249.000 100%
2021 -740.000 66.35%
2022 4.746.000 115.59%
2023 -1.736.000 373.39%

Net income in stock investing is like the money a company actually gets to keep as profit after paying all its bills, and it's an important measure to understand how well a company is doing financially.

Scancell Holdings plc Net Profit
Year Net Profit Growth
2008 -786.000
2009 -1.737.000 54.75%
2010 -1.649.000 -5.34%
2011 557.058 396.02%
2012 -1.901.944 129.29%
2013 -2.222.954 14.44%
2014 -2.414.630 7.94%
2015 -2.583.273 6.53%
2016 -3.544.979 27.13%
2017 -4.194.509 15.49%
2018 -5.627.487 25.46%
2019 -5.506.000 -2.21%
2020 -5.506.000 0%
2020 -15.477.000 64.42%
2021 -2.065.000 -649.49%
2022 -11.936.000 82.7%
2023 -10.192.000 -17.11%

EPS, or earnings per share, is a measure that shows how much profit a company has earned for each outstanding share of its stock, and it is important for stock investors as it helps understand the profitability of a company and compare it with other companies in the market.

Scancell Holdings plc Earning per Share (EPS)
Year Earning per Share (EPS) Growth
2008 0
2009 0 0%
2010 0 0%
2011 0 0%
2012 0 0%
2013 0 0%
2014 0 0%
2015 0 0%
2016 0 0%
2017 0 0%
2018 0 0%
2019 0 0%
2020 0 0%
2020 0 0%
2021 0 0%
2022 0 0%
2023 0 0%

Cashflow Statements

Cashflow statements show the movement of money in and out of a company, helping stock investors understand how much money a company makes and spends. By examining cashflow statements, investors can assess if a company is generating enough cash to pay its bills, invest in growth, and provide returns to stockholders.

Free cash flow is the leftover cash that a company generates after covering its operating expenses and capital expenditures, which is important for stock investors as it shows how much money a company has available to invest in growth, pay dividends, or reduce debt.

Scancell Holdings plc Free Cashflow
Year Free Cashflow Growth
2008 -1.082.000
2009 -1.386.000 21.93%
2010 -1.777.000 22%
2011 816.308 317.69%
2012 -2.067.724 139.48%
2013 -2.116.297 2.3%
2014 -2.638.747 19.8%
2015 -2.330.744 -13.21%
2016 -3.908.545 40.37%
2017 -4.074.160 4.07%
2018 -7.020.611 41.97%
2019 -7.035.613 0.21%
2020 -4.799.000 -46.61%
2020 -1.199.750 -300%
2021 -8.547.000 85.96%
2022 -8.343.000 -2.45%
2023 -6.666.000 -25.16%

Operating cash flow represents the cash generated or consumed by a company's day-to-day operations, excluding external investing or financing activities, and is crucial for stock investors as it shows how much cash a company is generating from its core business operations.

Scancell Holdings plc Operating Cashflow
Year Operating Cashflow Growth
2008 -1.059.000
2009 -1.314.000 19.41%
2010 -1.777.000 26.06%
2011 859.620 306.72%
2012 -1.998.331 143.02%
2013 -2.093.367 4.54%
2014 -2.638.747 20.67%
2015 -2.330.744 -13.21%
2016 -3.847.466 39.42%
2017 -4.062.747 5.3%
2018 -7.017.947 42.11%
2019 -7.032.949 0.21%
2020 -4.772.000 -47.38%
2020 -1.193.000 -300%
2021 -7.803.000 84.71%
2022 -8.140.000 4.14%
2023 -6.653.000 -22.35%

Capex, short for capital expenditures, refers to the money a company spends on acquiring or upgrading tangible assets like buildings, equipment, or technology, which is important for stock investors as it indicates how much a company is investing in its infrastructure to support future growth and profitability.

Scancell Holdings plc Capital Expenditure
Year Capital Expenditure Growth
2008 23.000
2009 72.000 68.06%
2010 0 0%
2011 43.312 100%
2012 69.393 37.58%
2013 22.930 -202.63%
2014 0 0%
2015 0 0%
2016 61.079 100%
2017 11.413 -435.17%
2018 2.664 -328.42%
2019 2.664 0%
2020 27.000 90.13%
2020 6.750 -300%
2021 744.000 99.09%
2022 203.000 -266.5%
2023 13.000 -1461.54%

Balance Sheet

Balance sheets provide a snapshot of a company's financial health and its assets (such as cash, inventory, and property) and liabilities (like debts and obligations) at a specific point in time. For stock investors, balance sheets help assess the company's overall worth and evaluate its ability to meet financial obligations and support future growth.

Equity refers to the ownership interest or stake that shareholders have in a company, representing their claim on its assets and earnings after all debts and liabilities are paid.

Scancell Holdings plc Equity
Year Equity Growth
2008 5.254.000
2009 6.048.000 13.13%
2010 4.636.000 -30.46%
2011 6.971.337 33.5%
2012 5.092.145 -36.9%
2013 9.077.264 43.9%
2014 6.754.002 -34.4%
2015 9.992.281 32.41%
2016 6.499.325 -53.74%
2017 13.940.950 53.38%
2018 9.336.848 -49.31%
2019 9.336.848 0%
2020 7.648.000 -22.08%
2021 19.485.000 60.75%
2022 -6.233.000 412.61%
2023 -3.505.000 -77.83%

Assets represent the valuable resources that a company owns, such as cash, inventory, property, and equipment, and understanding a company's assets helps investors assess its value and potential for generating future profits.

Scancell Holdings plc Assets
Year Assets Growth
2008 5.421.000
2009 6.500.000 16.6%
2010 4.758.000 -36.61%
2011 7.255.720 34.42%
2012 5.407.259 -34.18%
2013 9.614.855 43.76%
2014 7.357.914 -30.67%
2015 10.567.932 30.38%
2016 7.031.204 -50.3%
2017 14.637.040 51.96%
2018 10.542.258 -38.84%
2019 10.542.258 0%
2020 8.818.000 -19.55%
2021 49.058.000 82.03%
2022 30.270.000 -62.07%
2023 23.576.000 -28.39%

Liabilities refer to the financial obligations or debts that a company owes to creditors or external parties, and understanding a company's liabilities is important for investors as it helps assess the company's financial risk and ability to meet its obligations.

Scancell Holdings plc Liabilities
Year Liabilities Growth
2008 167.000
2009 452.000 63.05%
2010 122.000 -270.49%
2011 284.383 57.1%
2012 315.114 9.75%
2013 537.591 41.38%
2014 603.912 10.98%
2015 575.651 -4.91%
2016 531.879 -8.23%
2017 696.090 23.59%
2018 1.205.410 42.25%
2019 1.205.410 0%
2020 1.170.000 -3.03%
2021 29.573.000 96.04%
2022 36.503.000 18.98%
2023 27.081.000 -34.79%

Scancell Holdings plc Financial Ratio (TTM)

Valuation Metrics

Revenue per Share
0.01
Net Income per Share
-0.01
Price to Earning Ratio
-9.59x
Price To Sales Ratio
23.37x
POCF Ratio
-10.14
PFCF Ratio
-11.43
Price to Book Ratio
-30.97
EV to Sales
24.33
EV Over EBITDA
-10.76
EV to Operating CashFlow
-11.97
EV to FreeCashFlow
-11.9
Earnings Yield
-0.1
FreeCashFlow Yield
-0.09
Market Cap
0,12 Bil.
Enterprise Value
0,13 Bil.
Graham Number
0.04
Graham NetNet
-0.01

Income Statement Metrics

Net Income per Share
-0.01
Income Quality
0.95
ROE
1.91
Return On Assets
-0.48
Return On Capital Employed
-0.74
Net Income per EBT
0.82
EBT Per Ebit
1.07
Ebit per Revenue
-2.43
Effective Tax Rate
0.18

Margins

Sales, General, & Administrative to Revenue
0
Research & Developement to Revenue
2.37
Stock Based Compensation to Revenue
0
Gross Profit Margin
0.73
Operating Profit Margin
-2.43
Pretax Profit Margin
-2.61
Net Profit Margin
-2.15

Dividends

Dividend Yield
0
Dividend Yield %
0
Payout Ratio
0
Dividend Per Share
0

Operating Metrics

Operating Cashflow per Share
-0.01
Free CashFlow per Share
-0.01
Capex to Operating CashFlow
-0.01
Capex to Revenue
0.01
Capex to Depreciation
0.08
Return on Invested Capital
-0.64
Return on Tangible Assets
-0.48
Days Sales Outstanding
0
Days Payables Outstanding
380.09
Days of Inventory on Hand
0
Receivables Turnover
0
Payables Turnover
0.96
Inventory Turnover
0
Capex per Share
0

Balance Sheet

Cash per Share
0,02
Book Value per Share
0,00
Tangible Book Value per Share
-0
Shareholders Equity per Share
-0
Interest Debt per Share
0.02
Debt to Equity
-5.67
Debt to Assets
0.84
Net Debt to EBITDA
-0.42
Current Ratio
3.42
Tangible Asset Value
0,00 Bil.
Net Current Asset Value
-0,01 Bil.
Invested Capital
17187000
Working Capital
0,02 Bil.
Intangibles to Total Assets
0
Average Receivables
0,00 Bil.
Average Payables
0,00 Bil.
Average Inventory
0
Debt to Market Cap
0.16

Dividends

Dividends in stock investing are like rewards that companies give to their shareholders. They are a portion of the company's profits distributed to investors, typically in the form of cash payments, as a way for them to share in the company's success.

Scancell Holdings plc Dividends
Year Dividends Growth

Scancell Holdings plc Profile

About Scancell Holdings plc

Scancell Holdings plc, a clinical stage biopharmaceutical company, engages in the discovery and development of novel vaccines and antibody medicines to treat unmet needs in cancer and infectious diseases. The company's product candidates include SCIB1, which is in phase II clinical trial for the treatment of metastatic melanoma; SCIB2 for the treatment of non-small cell lung cancer; and Modi-1 that is in phase I/II clinical trials for the treatment of head and neck, triple negative breast, ovarian, and renal cancers. It also develops Modi-2, which targets homocitrullinated cancer antigens. In addition, the company develops SCOV1 and SCOV2 COVIDITY, a prophylactic DNA vaccine against the SARS-CoV-2 virus. Scancell Holdings plc was founded in 1997 and is based in Oxford, the United Kingdom.

CEO
Prof. Lindy Gillian Durrant Ph
Employee
61
Address
Unit 202 Bellhouse Building
Oxford, OX4 4GD

Scancell Holdings plc Executives & BODs

Scancell Holdings plc Executives & BODs
# Name Age
1 Mr. Sathijeevan Nirmalananthan
Chief Financial Officer, Company Secretary & Director
70
2 Dr. Samantha Paston Ph.D.
Head of Translational Research
70
3 Dr. Adrian Parry Ph.D.
Head of Manufacturing
70
4 Prof. Lindy Gillian Durrant Ph.D.
Founder, Chief Executive Officer, Chief Scientific Officer & Director
70
5 Dr. Mandeep Sehmi
Head of Business Development
70
6 Dr. Callum Scotthasbeen
Head of Development
70
7 Mr. Alex Hayward
Head of Finance
70
8 Dr. Nermeen Varawalla DPhil, M.B.A., M.D., MBA, Ph.D.
Chief Medical Officer
70

Scancell Holdings plc Competitors

ValiRx plc Logo
ValiRx plc

VAL.L

(1.0)
ImmuPharma plc Logo
ImmuPharma plc

IMM.L

(0.8)
ReNeuron Group plc Logo
ReNeuron Group plc

RENE.L

(1.5)
Avacta Group Plc Logo
Avacta Group Plc

AVCT.L

(0.0)
genedrive plc Logo
genedrive plc

GDR.L

(0.8)